Originally approved by the FDA in September 2023, Biogen's Tofidence became the first tocilizumab biosimilar available in the ...

CVS Caremark, Express Scripts and Optum Rx — the three largest pharmacy benefit managers in the U.S. — each excluded more ...

The US Food and Drug Administration (FDA ... for all indications of the reference product denosumab (Prolia/Xgeva). The biosimilar will launch in the United States in June 2025 as part of a ...

The Food and Drug Administration has approved Fresenius Kabi's Biologics License Application for the denosumab biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht). These ...

A settlement between Amgen and Fresenius Kabi will permit the biosimilar to launch in mid-2025 in the U.S. The FDA has approved two new denosumab biosimilars that are interchangeable with the ...

FDA commissioner Scott Gottlieb said: “Bringing new biosimilars to patients is a top priority for the FDA, and a key part of our efforts to help promote competition that can reduce drug costs an ...

Biosimilars are near-copies of complex biologic drugs grown in cells, that have been analysed and tested in trials showing that they have the same safety and efficacy profile as the originator drug.

Stimulants are most commonly prescribed as a first-line treatment for ADHD. Examples of brand-name drugs include Vyvanse, Adderall, and Ritalin. However, negative side effects may be common.

Other Prolia biosimilars include Jubbonti, Ospomyv and Stoboclo. Additional Xgeva biosimilars include Wyost, Xbryk and Osenvelt. Although the active drug ingredient in Conexxence and and Bomyntra is ...

We’d like to speak with personnel from the Department of Health and Human Services or its component agencies about what’s happening within the federal health bureaucracy. Please message us on Signal ...

Mar. 31, 2025 — New research reveals that lower proportions of specific sleep stages are associated with reduced brain volume in regions vulnerable to the development of Alzheimer's disease over ...